Loading
A phase 3 trial of Pemetrexed, Cisplatin, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Allist Pharmaceuticals, Inc., now recruiting.
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation is a phase 3 interventional study registered as NCT06956001 by Allist Pharmaceuticals, Inc., with 300 participants planned, started 2024-11-19 and due to reach its primary completion in 2027-12. Interventions recorded: Firmonertinib Mesilate Tablets, Pemetrexed Disodium for Injection, Cisplatin for injection, Carboplatin Injection. Conditions listed: EGFR, NSCLC (Advanced Non-small Cell Lung Cancer). No results are recorded here; the registry entry is the source.
Shares Shanghai Allist Pharmaceuticals, Pemetrexed, EGFR-mutated non-small-cell lung cancer, Cisplatin.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Cisplatin, Carboplatin.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Cisplatin, Carboplatin.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, EGFR-mutated non-small-cell lung cancer, Cisplatin, Carboplatin.